Kudos Launches Showcase to Increase the Public’s Understanding of the Future Role of AI

As we use artificial intelligence (AI) in more parts of everyday life, more people are questioning how it works, how it is applied and if they should trust it. To provide the public with these answers, some of the most influential academic publishers have partnered together to launch the Artificial Intelligence Knowledge Cooperative, collated by, Kudos, the platform for showcasing science.

The Showcase will provide better access to credible research about AI and its usage in easy-to-understand summaries.

According to a 2022 report by Tortoise Intelligence, worldwide investment into AI companies has increased by 115 per cent since 2020, marking the largest year-on-year growth in AI investment for at least two decades. Despite its integration into our lives, some businesses and members of the public are unsure about the impact of AI.

Kudos developed the AI knowledge cooperative, alongside publishers such as the Association for Computing Machinery, AIP Publishing, ASTM International and IOP Publishing, to provide media, industry, policy makers and the public with credible information that will help them understand the current and future role of AI. Each piece of research has been summarised into easy-to-understand language by expert writers to ensure everyone can access this research.

“From chatbots to self-driving vehicles, we are beginning to get used to AI in everyday life,” explained Charlie Rapple, chief customer officer and co-founder of Kudos. “As AI becomes more widespread, the public only has increasing questions about the impact the technology will have on our way of life, number of jobs and level of human interaction.

“Many questions about AI are already being answered by research in the field, so researchers have a big role to play in educating the public about an increasingly powerful and pervasive technology. Commonly only research papers published in high tier journals will be read, so this platform acts to increase the amount of vital research being read by the public and influential researchers in the AI industry,” concluded Rapple.

The curated content will focus on several areas of AI, such as the impact of hyperintelligence, regulations and ethics around the use of AI, how AI can assist with disease prevention and artificial moral agents.

The initiative will help develop trust and understanding between the research community and the public. It will help decision makers make more informed decisions about technologies they invest in, encourage people to adopt AI in their own homes and reduce the fear or distrust that is occurring around the technology.

To explore the most influential and insightful AI research for yourself, visit the collection here.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.